Not applicableAvailableNCT05650476What this trial is testingPre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)Who this might be right forMetastatic Castration-Resistant Prostate Cancer Pfizer
Early research (Phase 1)Study completedNCT03276572What this trial is testingPhase I Trial of 225Ac-J591 in Patients With mCRPCWho this might be right forProstate Cancer Weill Medical College of Cornell University 32
Post-approval studies (Phase 4)Looking for participantsNCT06099093What this trial is testingPilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide TetraxetanWho this might be right forProstate CancerMetastatic Castration-resistant Prostate CancerMetastatic Castration-resistant Prostate Carcinoma Brigham and Women's Hospital 30
Not applicableUnknownNCT02362620What this trial is testingPROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.Who this might be right forAdvanced Prostate CancerCabazitaxelDocetaxel Centro Nacional de Investigaciones Oncologicas CARLOS III 402
Not applicableStudy completedNCT06809426What this trial is testingEvaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate CancerWho this might be right forPSMA PET-Positive Castration-Resistant Prostate Cancer Affiliated Hospital of Jiangnan University 13
Not applicableStudy completedNCT00636090What this trial is testingMolecular, Genetic, and Genomic Assessments From Patients Treated With RAD001Who this might be right forMetastatic Hormone Refractory Prostate Cancer Duke University 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT03682289What this trial is testingCeralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid TumorsWho this might be right forClear Cell Renal Cell CarcinomaLocally Advanced Pancreatic CancerLocally Advanced Malignant Solid Neoplasm+10 more Rahul Aggarwal 83
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07104643What this trial is testingStudy of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）Who this might be right formCRPC TYK Medicines, Inc 48
Testing effectiveness (Phase 2)Looking for participantsNCT05766371What this trial is testingPembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate CancerWho this might be right forCastrate Resistant Prostate CancerMetastatic Castration-resistant Prostate CancerProstate Cancer+1 more University of California, San Francisco 48
Early research (Phase 1)Study completedNCT01792687What this trial is testingSafety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone AcetateWho this might be right forProstate Cancer Aragon Pharmaceuticals, Inc. 6
Not applicableStudy completedNCT03328364What this trial is testingA Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in SwedenWho this might be right forMetastatic Castration Resistant Prostate Cancer Astellas Pharma a/s 211
Very early researchStudy completedNCT05725070What this trial is testingPhase 0/1 Study of 212Pb-NG001 in mCRPCWho this might be right forMetastatic Castration-resistant Prostate Cancer ARTBIO Inc. 3
Testing effectiveness (Phase 2)Study completedNCT04869488What this trial is testingA Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate CancerWho this might be right forMetastatic Castration Resistant Prostate Cancer Jiangsu HengRui Medicine Co., Ltd. 93
Testing effectiveness (Phase 2)UnknownNCT05262608What this trial is testingThe Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene MutationWho this might be right forProstate CancerProstate CarcinomaMetastatic Castration-resistant Prostate Cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 30
Testing effectiveness (Phase 2)Ended earlyNCT03999515What this trial is testingErdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate CancerWho this might be right forCastration-Resistant Prostate CarcinomaDouble-Negative Prostate CarcinomaMetastatic Prostate Carcinoma+4 more University of Washington 3
Not applicableActive Not RecruitingNCT04024475What this trial is testingProstate Cancer BiobankWho this might be right forProstatic Neoplasms Swiss Cancer Institute 1,323
Not applicableStudy completedNCT02380274What this trial is testingObservational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)Who this might be right forProstate CancerCastration-resistant Prostate CancerMetastatic Prostate Cancer Astellas Pharma Global Development, Inc. 1,030
Not applicableStudy completedNCT01812668What this trial is testingCabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate CancerWho this might be right forAdenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate Cancer+1 more Barbara Ann Karmanos Cancer Institute 20
Testing effectiveness (Phase 2)Ended earlyNCT04716725What this trial is testing68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate CancerWho this might be right forCastration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IV Prostate Cancer AJCC v8+2 more Thomas Hope 15
Post-approval studies (Phase 4)Study completedNCT02485691What this trial is testingCabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted AgentWho this might be right forProstate Cancer Metastatic Sanofi 255